Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Corroborated by 2 sources from 2 publishers
globalbusiness1d ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, key Points - - Commercial and MCM momentum: Medical countermeasures comprised 37% international MCM revenue and the quarter included wins such as a $140 million Canada agreement, a $54 million VIGIV award and a ~$21.5 million BioThrax DoD order, while the NARCAN franchise expanded with FDA‑approved carrying case and multi‑pack launches supporting continued leadership.